U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584018) titled 'The DoHAICs Study Expansion Phase' on Dec. 22, 2025.
Brief Summary: We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
Study Start Date: May 20
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
DRUG: Donafenib
Donafenib (200 mg twice daily, taken orally, initiated 3-7 days before the first HAIC session)
DRUG: sintilimab
sintilimab (200 mg intravenously every 3 weeks, administered 0-1 day before each HAIC treatment)
PROCEDURE: HAIC
HAIC (oxaliplatin ...